Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40
Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121
Recent Health Care Deals, week ending 04.01.2016
AcquirerTargetPrice DiaSorin S.p.A.Focus Diagnostics Inc. $300 million Sun Pharmaceutical Industries Ltd.14 prescription drug brands$293 million Encore Rehabilitation Services, LLCContract therapy business$65 million PuraCap PharmaceuticalsEpic Pharma, LLC$550 million MEDNAX, Inc. Mid-Missouri Neonatology,... Read More »Sun Pharma Buys into Japanese Drug Market
Sun Pharmaceutical Industries Ltd. (BSE: 524715) last week paid $293 million for 14 “established prescription” drug brands currently being marketed by Novartis AG (NYSE: NVS) in Japan. Under terms of the agreement, Novartis will continue to distribute these unidentified brands for a certain period, pending transfer of all marketing authorizations to Sun Pharma’s subsidiary. The acquired brands will then be marketed by an established marketing partner under the Sun Pharma label. This transaction expands Sun’s footprint in Japan’s $73 billion pharmaceutical market. Read More »Bankrupt Hospital M&A Up in Non-Expansion States
Has the decision to expand or not to expand Medicaid impacted merger and acquisition activity among hospitals and health systems? With only two years’ worth of data (2014 and 2015), it’s still early to draw definitive conclusions. So consider the following data as anecdotal evidence of the economic impact the various state governments have brought to bear on healthcare providers in their states. Mergers and acquisitions among all types of hospitals—acute care, long-term care, critical access, etc.—in the Medicaid expansion states increased from 49 deals in 2014 to 56 deals in 2015. Hospitals and health systems based in non-expansion states saw M&A activity decrease in the same time... Read More »Meridian Targets Magellan Biosciences
Lead poisoning has been a prominent news story this year, thanks to the tragic circumstances now playing out in Flint, Michigan. So it’s no surprise that Magellan Biosciences, Inc. and its subsidiary, Magellan Diagnostics, Inc., have been sold to Meridian Bioscience, Inc. (NASDAQ: VIVO) for $66 million. Majority owner Ampersand Capital Partners, together with Tekla Capital Management and Boston Community Venture Fund, made their exit from the business. Magellan has built a national reputation for point-of-care testing kits that measure levels of lead in the bloodstream. Its LeadCare® II, LeadCare Ultra and Plus systems are used by more than 6,500 physician offices and clinics in the... Read More »Advent International Acquires ATI Physical Therapy
Private equity continues to invest in rehabilitation companies. The latest deal, the fifth of five announced in March 2016, is from Advent International, a Boston-based firm with more than $30 billion invested in 310 companies. For an undisclosed price, the firm took a majority interest in ATI Physical Therapy, a portfolio company of KRG Capital. ATI specializes in outpatient rehabilitation and adjacent healthcare services. It operates more than 500 clinics in 19 states, and served nearly 300,000 unique patients in 2015. Read More »Recent Health Care Deals, week ending 03.25.2016
AcquirerTargetPrice Bristol-Myers Squibb Padlock Therapeutics, Inc. $225 million Capella Healthcare, Inc.$550 million Capitol Senior Living2 assisted living communities$48 million Syncordia Technologies and Healthcare SolutionsBilling Solutions, Inc. $8 million Baptist Health South FloridaNorthpoint Surgery... Read More »Home Health in March: Five Deals and a Bankruptcy
The Home Health & Hospice sector had a very slow year in 2015, with just 47 deals made public. Deal making activity has picked up quite a bit in 2016, with 12 deals in the first two months and five more in the first three weeks of March. The only deal to report a price was the $84 million acquisition of Genesis Healthcare’s (NYSE: GEN) home health and hospice business, by Compassus. Genesis is selling the majority of its home health and hospice operations, which are located in California, Idaho, Montana and New Mexico. Privately-held Compassus is a nationwide network of community-based post-acute care services primarily focused on hospice, palliative and home health care. In... Read More »Biotechnology CROs Are Trading Again
Two contract research organizations (CROs) have changed hands in the past two weeks. On March 17, Hamburg, Germany-based IPM Biotech was acquired by BioAgilytix, a portfolio company of Riverside Partners, in Durham, North Carolina. As its name implies, IPM Biotech specializes in biotech research, specifically in large molecule bioanalysis in the area of immunogenicity. The transaction expands BioAgilytix’s global footprint with IPM’s newly planned GLP and GMB laboratory facility. Its services complement IPM’s rich immunogenicity, pharmacokinetics and pharmacodynamics expertise. Less than a week later, LakePharma, Inc., a CRO in Belmont, California, acquired Blue Sky... Read More »Two For-Profit Hospital Systems Merge
Two hospital chains that changed hands only last year announced their merger on March 22. RegionalCare Health Partners Inc., based in Brentwood, Tennessee, and Capella Healthcare, Inc., located in nearby Franklin, will form RCCH Health Partners when the deal closes in the second quarter. The combined system will have 18 hospital campuses in 12 states with more than 13,000 employees, 2,000 affiliated physicians and $1.7 billion in revenue. Only last July, Capella Healthcare was sold by GTCR to Medical Properties Trust, Inc. (MPT) and Capella management for approximately $900 million. In November, Apollo Global Management (NYSE: APO) paid an undisclosed price for RegionalCare, which was then... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
